我們已在上線！進一步了解

ADMA Biologics

ADMA

市值 US$23.9億

10.68 USD

-0.05

0.47%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

10.68

0.00

0%

1天

-0.47%

5天

3.49%

1個月

20%

3個月

21.23%

6個月

-0.56%

今年迄今

-40.27%

1年

-26.65%

5年

870.91%

10年

68.72%

關於： ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

員工： 647

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 2.6%

中性 95.4%

負面 2.1%

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield

ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process

Zacks Investment Research

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Zacks Investment Research

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

Zacks Investment Research

ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.

ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

Zacks Investment Research

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Zacks Investment Research

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

Zacks Investment Research

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)

Zacks Investment Research

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

查看新聞排名

價格圖表採用Lightweight Charts™實作